Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Sirius Therapeutics, announced it has dosed the first subject in a…